English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/125344
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Targeting the dream protein: new avenues for the search of drugs for neurodegenerative diseases

AutorCercós, Pilar ; García-López, M. Teresa ; Herranz, Rosario ; Martín-Martínez, Mercedes ; Prieto, Ángela ; Valenzuela, Carmen ; Naranjo, José Ramón; Gutiérrez-Rodríguez, Marta
Fecha de publicación2013
EditorSociedad Española de Química Terapéutica
CitaciónIII SEQT Summer School (2013)
ResumenAltered neuronal calcium homeostasis and early compensatory changes in transcriptional programs are common features of many neurodegenerative pathologies including Alzheimer’s disease (AD), Down syndrome (DS) and Huntington’s disease (HD). DREAM (Downstream Regulatory Element Antagonist Modulator), also known as calsenilin or KChIP-3 (potasium channel interacting protein-3), is a multifunctional Ca2+ binding protein that controls the expression level and/or the activity of several proteins related to Ca2+ homeostasis, neuronal excitability and neuronal survival. This protein is widely expressed in the brain and, depending on the cell type and physiological conditions, shows multiple subcellular localizations, in the nucleus, cytosol or cell membrane. Initially, the interest in DREAM was based on its key role in the regulation of intracelular Ca2+ levels. An early reduction in DREAM levels is found in the pre-symptomatic phase of several neurodegenerative mouse models, including AD, DS and HD. These data support the idea that an early down regulation of the DREAM level in neurons during the pre-symptomatic phase of the AD, DS and HD might be part of its neuroprotective mechanism. These findings suggest that DREAM could be a novel and versatile target for therapeutic intervention in neurodegeneration and that molecules able to bind to DREAM and block its physiological functions could be candidates of drugs to treat neurodegenerative diseases. Up to know, low molecular weight molecules have not been described able to interact with DREAM and to modulate its action. In this communication we report the rational design, the synthesis and the biological evaluation of novel DREAM-binding molecules.
DescripciónResumen del póster presentado al III SEQT Summer School: "Medicinal Chemistry in Drug Discovery: The Pharma Perspective", celebrado en Tres Cantos (Madrid) del 25 al 27 de junio de 2013.
URIhttp://hdl.handle.net/10261/125344
Aparece en las colecciones: (IIBM) Comunicaciones congresos
(IQM) Comunicaciones congresos
(CNB) Comunicaciones congresos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.